戻る Agenda
Session 4 Track 3 - New Realities: An Update on the Legislative and Regulatory Modernization Initiative
Session Chair(s)
Rocelyn DelCarmen
Director, Regulatory Affairs and Quality Assurance
Astrazeneca Canada Inc., Canada
Hear an update from Health Canada’s Office of Legislative and Regulatory Modernization on the status of the regulatory roadmap activities. Get Health Canada and Industry’s insight about topics that will likely be addressed as the next phase of the roadmap is tackled, including topics such as product classification (e.g. Drug vs OTC vs NHP) and the resetting of Divisions 1 and 8 of the FDA & R.
Speaker(s)
Priorities for Upcoming LRM Initiatives - The Perspective of Consumer Health Products Manufacturers
Anuradha Rao, MSc
Health Canada, Canada
Scientific and Regulatory Affairs Officer, Consumer Health Products Canada
Update on Regulatory Modernization in HPFB
Barbara Wong, PhD
Health Canada, Canada
Senior Policy Analyst, Policy and Promotion Division
Priorities for Upcoming LRM Initiatives – The Perspective of Multi-National Innovative Pharmaceutical Companies
Loretta Del Bosco
AbbVie Corporation, Canada
Director, Regulatory Affairs Quality Assurance Operations